Literature DB >> 1352414

Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1.

B P Sorrentino1, S J Brandt, D Bodine, M Gottesman, I Pastan, A Cline, A W Nienhuis.   

Abstract

Experiments were performed to determine if retroviral-mediated transfer of the human multidrug resistance 1 gene (MDR1) into murine bone marrow cells would confer drug resistance to the cells and whether the MDR1 gene could be used as a dominant selectable marker in vivo. When mice transplanted with bone marrow cells containing a transferred MDR1 gene were treated with the cytotoxic drug taxol, a substantial enrichment for transduced bone marrow cells was observed. This demonstration of positive selection establishes the ability to amplify clones of transduced hematopoietic cells in vivo and suggests possible applications in human therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352414     DOI: 10.1126/science.1352414

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  51 in total

1.  Efficient c-kit receptor-targeted gene transfer to primary human CD34-selected hematopoietic stem cells.

Authors:  Q Zhong; P Oliver; W Huang; D Good; V La Russa; Z Zhang; J R Cork; R W Veith; C Theodossiou; J K Kolls; P Schwarzenberger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 2.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

3.  Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo.

Authors:  W Pfutzner; A Terunuma; C L Tock; E K Snead; T M Kolodka; M M Gottesman; L Taichman; J C Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 4.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

5.  Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow.

Authors:  Katrin Hacke; Akos Szakmary; Andrew R Cuddihy; Nora Rozengurt; Nathan A Lemp; Jiri Aubrecht; Gregory W Lawson; Nagesh P Rao; Gay M Crooks; Robert H Schiestl; Noriyuki Kasahara
Journal:  Exp Hematol       Date:  2011-10-12       Impact factor: 3.084

Review 6.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 7.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

8.  Targeted expansion of genetically modified bone marrow cells.

Authors:  L Jin; N Siritanaratkul; D W Emery; R E Richard; K Kaushansky; T Papayannopoulou; C A Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.

Authors:  W R Smythe; H C Hwang; A A Elshami; K M Amin; S L Eck; B L Davidson; J M Wilson; L R Kaiser; S M Albelda
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

10.  In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.

Authors:  J A Schroeder; Y Chen; J Fang; D A Wilcox; Q Shi
Journal:  J Thromb Haemost       Date:  2014-07-17       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.